◀ Back to MTOR
MTOR — PTBP2
Text-mined interactions from Literome
Wang et al., J Clin Invest 2013
:
Rapamycin, an
mTOR inhibitor used clinically to suppress T cell responses, also
acts on
DCs , rendering them tolerogenic
Pan et al., J Immunol 2013
:
Its deficiency in
DCs results in increased mammalian target of rapamycin (mTOR) complex 1 but decreased
mTORC2 signaling, altered cytokine production, impaired CIITA/MHC-II expression, and defective Ag presentation to CD4 T cells after TLR4 stimulation